Pegaptanib: choroidal neovascularization in patients with age-related macular degeneration and previous arterial thromboembolic events

M Battaglia Parodi, E Di Bartolo, C Brue, E Cappello, C Furino, S Giuffrida, M Imparato, M Reibaldi

Research output: Contribution to journalArticle

Abstract

PURPOSE: To evaluate the efficacy and the rate of side effects of the pegylated aptamer pegaptanib in the treatment of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and a history of previous arterial thromboembolic events (ATEs). METHODS: Twenty-three eyes of 23 patients with subfoveal CNV due to AMD and cerebrovascular accidents (n = 12) and myocardial infarction (n = 11) in the previous 6 months received intravitreal pegaptanib 0.3 mg according to a pro re nata regimen and were followed for 12 months. The paired Student t test was used to evaluate mean changes in best-corrected visual acuity (BCVA; primary outcome measure) and central foveal thickness (CFT). RESULTS: The mean patient age was 71.5 ± 4.6 years; there were 14 women and 9 men. The CNV was type 1, 2, and 3 in 18, 3, and 2 eyes, respectively. The mean BCVA improved from 0.67 ± 0.23 logMAR at baseline to 0.52 ± 0.31 logMAR at the end of 12-month follow-up (p = 0.044). Thirty-five percent of patients achieved ≥3 Early Treatment Diabetic Retinopathy Study lines improvement at 12 months. Mean CFT at baseline (381 ± 111 µm) decreased to 304 ± 82 µm at 12 months (p = 0.008). Patients received a mean of 4.3 ± 1.3 (range 3-7) injections. No systemic or ocular side effects occurred; no patient experienced further ATEs. CONCLUSIONS: Intravitreal pegaptanib can be considered a viable treatment option for patients with AMD-related CNV who are at high risk of ATEs.
Original languageEnglish
Pages (from-to)58-62
Number of pages5
JournalEuropean Journal of Ophthalmology
Volume28
Issue number1
DOIs
Publication statusPublished - 2018

Fingerprint

Choroidal Neovascularization
Macular Degeneration
Diabetic Retinopathy
pegaptanib
Visual Acuity
Therapeutics
Stroke
Myocardial Infarction
Outcome Assessment (Health Care)
Students
Injections

Cite this

Pegaptanib: choroidal neovascularization in patients with age-related macular degeneration and previous arterial thromboembolic events. / Battaglia Parodi, M; Di Bartolo, E; Brue, C; Cappello, E; Furino, C; Giuffrida, S; Imparato, M; Reibaldi, M.

In: European Journal of Ophthalmology, Vol. 28, No. 1, 2018, p. 58-62.

Research output: Contribution to journalArticle

Battaglia Parodi, M ; Di Bartolo, E ; Brue, C ; Cappello, E ; Furino, C ; Giuffrida, S ; Imparato, M ; Reibaldi, M. / Pegaptanib: choroidal neovascularization in patients with age-related macular degeneration and previous arterial thromboembolic events. In: European Journal of Ophthalmology. 2018 ; Vol. 28, No. 1. pp. 58-62.
@article{a8f99d7fecac45f3a21f48ed08ae47e8,
title = "Pegaptanib: choroidal neovascularization in patients with age-related macular degeneration and previous arterial thromboembolic events",
abstract = "PURPOSE: To evaluate the efficacy and the rate of side effects of the pegylated aptamer pegaptanib in the treatment of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and a history of previous arterial thromboembolic events (ATEs). METHODS: Twenty-three eyes of 23 patients with subfoveal CNV due to AMD and cerebrovascular accidents (n = 12) and myocardial infarction (n = 11) in the previous 6 months received intravitreal pegaptanib 0.3 mg according to a pro re nata regimen and were followed for 12 months. The paired Student t test was used to evaluate mean changes in best-corrected visual acuity (BCVA; primary outcome measure) and central foveal thickness (CFT). RESULTS: The mean patient age was 71.5 ± 4.6 years; there were 14 women and 9 men. The CNV was type 1, 2, and 3 in 18, 3, and 2 eyes, respectively. The mean BCVA improved from 0.67 ± 0.23 logMAR at baseline to 0.52 ± 0.31 logMAR at the end of 12-month follow-up (p = 0.044). Thirty-five percent of patients achieved ≥3 Early Treatment Diabetic Retinopathy Study lines improvement at 12 months. Mean CFT at baseline (381 ± 111 µm) decreased to 304 ± 82 µm at 12 months (p = 0.008). Patients received a mean of 4.3 ± 1.3 (range 3-7) injections. No systemic or ocular side effects occurred; no patient experienced further ATEs. CONCLUSIONS: Intravitreal pegaptanib can be considered a viable treatment option for patients with AMD-related CNV who are at high risk of ATEs.",
author = "{Battaglia Parodi}, M and {Di Bartolo}, E and C Brue and E Cappello and C Furino and S Giuffrida and M Imparato and M Reibaldi",
year = "2018",
doi = "10.5301/ejo.5001060",
language = "English",
volume = "28",
pages = "58--62",
journal = "European Journal of Ophthalmology",
issn = "1120-6721",
publisher = "Wichtig Publishing",
number = "1",

}

TY - JOUR

T1 - Pegaptanib: choroidal neovascularization in patients with age-related macular degeneration and previous arterial thromboembolic events

AU - Battaglia Parodi, M

AU - Di Bartolo, E

AU - Brue, C

AU - Cappello, E

AU - Furino, C

AU - Giuffrida, S

AU - Imparato, M

AU - Reibaldi, M

PY - 2018

Y1 - 2018

N2 - PURPOSE: To evaluate the efficacy and the rate of side effects of the pegylated aptamer pegaptanib in the treatment of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and a history of previous arterial thromboembolic events (ATEs). METHODS: Twenty-three eyes of 23 patients with subfoveal CNV due to AMD and cerebrovascular accidents (n = 12) and myocardial infarction (n = 11) in the previous 6 months received intravitreal pegaptanib 0.3 mg according to a pro re nata regimen and were followed for 12 months. The paired Student t test was used to evaluate mean changes in best-corrected visual acuity (BCVA; primary outcome measure) and central foveal thickness (CFT). RESULTS: The mean patient age was 71.5 ± 4.6 years; there were 14 women and 9 men. The CNV was type 1, 2, and 3 in 18, 3, and 2 eyes, respectively. The mean BCVA improved from 0.67 ± 0.23 logMAR at baseline to 0.52 ± 0.31 logMAR at the end of 12-month follow-up (p = 0.044). Thirty-five percent of patients achieved ≥3 Early Treatment Diabetic Retinopathy Study lines improvement at 12 months. Mean CFT at baseline (381 ± 111 µm) decreased to 304 ± 82 µm at 12 months (p = 0.008). Patients received a mean of 4.3 ± 1.3 (range 3-7) injections. No systemic or ocular side effects occurred; no patient experienced further ATEs. CONCLUSIONS: Intravitreal pegaptanib can be considered a viable treatment option for patients with AMD-related CNV who are at high risk of ATEs.

AB - PURPOSE: To evaluate the efficacy and the rate of side effects of the pegylated aptamer pegaptanib in the treatment of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and a history of previous arterial thromboembolic events (ATEs). METHODS: Twenty-three eyes of 23 patients with subfoveal CNV due to AMD and cerebrovascular accidents (n = 12) and myocardial infarction (n = 11) in the previous 6 months received intravitreal pegaptanib 0.3 mg according to a pro re nata regimen and were followed for 12 months. The paired Student t test was used to evaluate mean changes in best-corrected visual acuity (BCVA; primary outcome measure) and central foveal thickness (CFT). RESULTS: The mean patient age was 71.5 ± 4.6 years; there were 14 women and 9 men. The CNV was type 1, 2, and 3 in 18, 3, and 2 eyes, respectively. The mean BCVA improved from 0.67 ± 0.23 logMAR at baseline to 0.52 ± 0.31 logMAR at the end of 12-month follow-up (p = 0.044). Thirty-five percent of patients achieved ≥3 Early Treatment Diabetic Retinopathy Study lines improvement at 12 months. Mean CFT at baseline (381 ± 111 µm) decreased to 304 ± 82 µm at 12 months (p = 0.008). Patients received a mean of 4.3 ± 1.3 (range 3-7) injections. No systemic or ocular side effects occurred; no patient experienced further ATEs. CONCLUSIONS: Intravitreal pegaptanib can be considered a viable treatment option for patients with AMD-related CNV who are at high risk of ATEs.

U2 - 10.5301/ejo.5001060

DO - 10.5301/ejo.5001060

M3 - Article

VL - 28

SP - 58

EP - 62

JO - European Journal of Ophthalmology

JF - European Journal of Ophthalmology

SN - 1120-6721

IS - 1

ER -